Cargando…

Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study

The indispensable role of the SARS-CoV-2 main protease (Mpro) in the viral replication cycle and its dissimilarity to human proteases make Mpro a promising drug target. In order to identify the non-covalent Mpro inhibitors, we performed a comprehensive study using a combined computational strategy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Jian-Xin, Du, Wen-Wen, Xia, Yuan-Ling, Zhang, Zhi-Bi, Yu, Ze-Fen, Fu, Yun-Xin, Liu, Shu-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959744/ https://www.ncbi.nlm.nih.gov/pubmed/36835648 http://dx.doi.org/10.3390/ijms24044237

Ejemplares similares

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors
por: Kim, Hoshin, et al.
Publicado: (2022)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Mechanistic Origin of Different Binding Affinities of SARS-CoV and SARS-CoV-2 Spike RBDs to Human ACE2
por: Zhang, Zhi-Bi, et al.
Publicado: (2022)

In silico assessment of diterpenes as potential inhibitors of SARS-COV-2 main protease
por: Abdelrady, Yousef A, et al.
Publicado: (2023)

In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking
por: Vázquez-Mendoza, Luis Heriberto, et al.
Publicado: (2022)

In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor
por: Wen, Lei, et al.
Publicado: (2021)

Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023)

Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
por: La Monica, Gabriele, et al.
Publicado: (2022)

An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study
por: Banerjee, Snehasis
Publicado: (2021)

Supercomputer simulation of the covalent inhibition of the main protease of SARS-CoV-2
por: Nemukhin, A. V., et al.
Publicado: (2022)

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
por: Lockbaum, Gordon J., et al.
Publicado: (2021)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

An in-silico investigation of potential natural polyphenols for the targeting of COVID main protease inhibitor
por: Aljarba, Nada H., et al.
Publicado: (2022)

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
por: Eleftheriou, Phaedra, et al.
Publicado: (2020)

In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
por: Xiong, Muya, et al.
Publicado: (2022)

2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies
por: Hariyono, Pandu, et al.
Publicado: (2022)

Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach
por: Farhat, Ameny, et al.
Publicado: (2022)

In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease
por: Gao, Menghan, et al.
Publicado: (2023)

Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
por: Ge, Rui, et al.
Publicado: (2022)

Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide
por: Yamane, Daiki, et al.
Publicado: (2022)

Boroleucine‐Derived Covalent Inhibitors of the ZIKV Protease
por: Braun, Niklas J., et al.
Publicado: (2022)

In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease
por: Yañez, Osvaldo, et al.
Publicado: (2021)

In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis
por: Harisna, Azza Hanif, et al.
Publicado: (2021)

In silico discovery of SARS-CoV-2 main protease inhibitors from the carboline and quinoline database
por: Muhtar, Eldar, et al.
Publicado: (2021)

In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from Thymus schimperi
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2023)

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
por: Brewitz, Lennart, et al.
Publicado: (2023)

DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors
por: Jimmidi, Ravikumar, et al.
Publicado: (2023)

Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis
por: Verma, Shalja, et al.
Publicado: (2021)

Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
por: Ngo, Chau, et al.
Publicado: (2023)

Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage
por: Shi, Tzu-Hau, et al.
Publicado: (2020)

Hordatines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach
por: Dahab, Mohammed A., et al.
Publicado: (2020)

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
por: Narkhede, Rohan R., et al.
Publicado: (2020)

Screening, molecular simulation & in silico kinetics of virtually designed covid-19 main protease inhibitors
por: Aleissa, Mohammed S., et al.
Publicado: (2022)

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors
por: Ibrahim, Mahmoud A.A., et al.
Publicado: (2020)

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method
por: Sencanski, Milan, et al.
Publicado: (2020)

In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M(pro))
por: Falade, Victoria Adeola, et al.
Publicado: (2021)

A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease
por: Elkaeed, Eslam B., et al.
Publicado: (2022)

High predictive QSAR models for predicting the SARS coronavirus main protease inhibition activity of ketone-based covalent inhibitors
por: Sepehri, Bakhtyar, et al.
Publicado: (2021)

Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease
por: Lipiński, Piotr F.J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g6joub5u9db6eslncbopdophl2